AZD 2066 is a selective, orally active and brain-penetrant antagonist of mGluR5. AZD 2066 has antinociception effects.
性状
Solid
IC50 & Target[1][2]
mGluR5
体外研究(In Vitro)
AZD 2066 (1-10 μM) inhibits Ca response, with IC50s of 27.2±9.1, 3.56±0.52, 96.2±17.8, and 380±78.0 nM in mGlu5/HEK cells and striatal, hippocampal, and cortical cultures respectively.AZD 2066 (1-10 μM) inhibits the oscillatory Ca response which induced by bath application of DHPG, and blocks either DHPG or Quis e?ects in mGlu5/HEK cells.AZD 2066 (1-10 μM) has less e?ective in striatal neurons. has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究(In Vivo)
AZD 2066 (0.3-30 mg/kg; p.o.) shows discriminative effects in rats. has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Model: Male Wistar rats (weighing 240-250 g)
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years;4°C 2 years
ClinicalTrial
参考文献
[1]. Swedberg MD, et al. AZD9272 and AZD2066: selective and highly central nervous system penetrant mGluR5 antagonists characterized by their discriminative effects. J Pharmacol Exp Ther. 2014 Aug;350(2):212-22.[2]. Jong YJI, et, al. Location and Cell-Type-Specific Bias of Metabotropic Glutamate Receptor, mGlu 5, Negative Allosteric Modulators. ACS Chem Neurosci. 2019 Nov 20; 10(11): 4558-4570.